Siyu He, Yuyao Xie, Yinan Zhu, Ziyue Wang, Lin Fu, Xuyong Lin
{"title":"Pulmonary papillary adenoma: comprehensive clinicopathologic analysis of 10 cases and molecular genetic analysis of 7 cases.","authors":"Siyu He, Yuyao Xie, Yinan Zhu, Ziyue Wang, Lin Fu, Xuyong Lin","doi":"10.1007/s00428-025-04162-x","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary papillary adenoma (PPA) constitutes a relatively uncommon type of lung neoplasm, which gives rise to a diagnostic intricacy. Owing to the paucity, our understanding of this disease remains far from comprehensive, and a thorough molecular investigation around PPA has been conspicuously lacking. The current study amassed a group of 10 cases of PPA that had been precisely diagnosed. We collected their clinical particulars and utilized next-generation sequencing (NGS) technology to examine the genetic mutations in 7 of these cases. The study population comprised 3 female and 7 male patients, with a median age of 52.9 years. The tumor sizes ranged from 0.8 to 3.8 cm. Seven patients were asymptomatic, while three patients manifested respiratory symptoms. Through the application of NGS, a wide array of mutation patterns was identified in the 7 cases, implicating pathways such as Wnt, RTK/RAS, PI3K, and Cell Cycle/Checkpoint. More precisely, mutations in genes such as MAP2K1 (1/7), AKT1 (1/7), NF1 (1/7), APC (2/7), EGFR (1/7), NBN (1/7), and CTNNB1 (1/7) were detected. The pathways most commonly involved were the Wnt pathway (3/7, APC and CTNNB1) and the RTK/RAS pathway (3/7, MAP2K1, NF1, and EGFR). As of now, all patients are still alive, without any evidence of recurrence or metastasis. This study has significantly enlarged the PPA case database and has suggested that PPA is a tumor type possessing unique and relatively complex molecular characteristics.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04162-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pulmonary papillary adenoma (PPA) constitutes a relatively uncommon type of lung neoplasm, which gives rise to a diagnostic intricacy. Owing to the paucity, our understanding of this disease remains far from comprehensive, and a thorough molecular investigation around PPA has been conspicuously lacking. The current study amassed a group of 10 cases of PPA that had been precisely diagnosed. We collected their clinical particulars and utilized next-generation sequencing (NGS) technology to examine the genetic mutations in 7 of these cases. The study population comprised 3 female and 7 male patients, with a median age of 52.9 years. The tumor sizes ranged from 0.8 to 3.8 cm. Seven patients were asymptomatic, while three patients manifested respiratory symptoms. Through the application of NGS, a wide array of mutation patterns was identified in the 7 cases, implicating pathways such as Wnt, RTK/RAS, PI3K, and Cell Cycle/Checkpoint. More precisely, mutations in genes such as MAP2K1 (1/7), AKT1 (1/7), NF1 (1/7), APC (2/7), EGFR (1/7), NBN (1/7), and CTNNB1 (1/7) were detected. The pathways most commonly involved were the Wnt pathway (3/7, APC and CTNNB1) and the RTK/RAS pathway (3/7, MAP2K1, NF1, and EGFR). As of now, all patients are still alive, without any evidence of recurrence or metastasis. This study has significantly enlarged the PPA case database and has suggested that PPA is a tumor type possessing unique and relatively complex molecular characteristics.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.